Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients

Abstract

Rituximab (RTX) combined with short-term glucocorticoids (GC) is an effective therapeutic option for pemphigus. The newly developed Glucocorticoid Toxicity Index (GTI) tool provides the possibility to measure GC toxicities over time. To compare 1-year GTI between two groups of RTX-treated and RTX-naïve patients with pemphigus. The responsiveness of the GTI was also investigated. A prospective cohort of 129 adults with newly diagnosed pemphigus was conducted. GC-related toxicities were assessed at 3-month intervals according to Composite and Specific lists of the GTI. Of the patients, 76.7% (n = 99) received RTX. Throughout the time intervals, RTX-treated patients had lower GTI compared to RTX-naïve ones (p = 0.036). The mean GTI at 1-year was 34.3 in the RTX-treated group and 50.8 in the RTX-naïve group (p = 0.04). The most commonly observed GC-related toxicity was neuropsychiatric manifestations for 34% (224 events). The relapse rate of RTX-treated patients (1%) was significantly lower than RTX-naïve patients (10%) (p = 0.037). The GTI showed no correlation with cumulative GC consumption in both groups (p > 0.05, both). Patients treated with GC alone had remarkably higher GTI than patients treated with GC plus RTX. The GTI is an applicable tool to quantitatively capture GC toxicities at the patient level in pemphigus.

Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992–2022)

“…Rituximab can be used alone to treat pemphigus [ 92 , 93 ] or in combination with glucocorticoids, corticosteroids, etc. [ [94] , [95] , [96] ]. However, rituximab increases the risk of Pneumocystis jiroveci pneumonia (PJP) and may have side effects such as urticaria and shingles [ [97] , [98] , [99] ].…”

A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy

“…Using corticosteroids alone or combined with steroid‐sparing immunosuppressants has helped control the disease. However, these conventional agents come with serious adverse events and morbidities, especially in long‐term use 7,8 . Therefore, dermatologists have constantly been challenged to choose the most efficient with the slightest complication therapeutic agents.…”

Pemphigus Disease and Area Index: Unmet needs in the real‐world management of pemphigus

“…

Pemphigus is a group of autoimmune diseases that cause intraepithelial blistering of the skin and mucous membranes, with potentially life-threatening consequences. Early diagnosis and treatment are crucial for managing pemphigus, which typically involves a combination of corticosteroids, rituximab, and other immunosuppressant drugs (Kianfer et al, 2022;Mazaherpour et al, 2022). Various scoring instruments have been developed over the past few decades to assess the severity and activity of autoimmune bullous diseases (AIBDs).

…”